We are live on ! Find out more
RAPT

RAPT Therapeutics
RAPT

Delisted

RAPT was delisted on the 2nd of March, 2026.

Back to rankings

108 hedge funds and large institutions have $895M invested in RAPT Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

104% more call options, than puts

Call options by funds: $15.3M | Put options by funds: $7.54M

55% more capital invested

Capital invested by funds: $578M → $895M (+$318M)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

13% more funds holding

Funds holding: 96 → 108 (+12)

6% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 36

0.44% more ownership

Funds ownership: 12.65% → 13.09% (+0.44%)

Holders
108
Holders Change
+12
Holders Change %
+12.5%
% of All Funds
1.57%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
21
Increased
38
Reduced
36
Closed
8
Calls
$15.3M
Puts
$7.54M
Net Calls
+$7.81M
Net Calls Change
-$1.86M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$20.6M
2
SC
Samlyn Capital
New York
+$11M
3
TCM
TimesSquare Capital Management
New York
+$7.8M
4
DTC
Deep Track Capital
Connecticut
+$4.55M
5
OCA
Octagon Capital Advisors
New York
+$4.52M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$14.9M
2
B
Braidwell
Connecticut
-$10.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$10.1M
4
GPP
Great Point Partners
Connecticut
-$5.54M
5
BC
Boxer Capital
California
-$4.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$7.21M +$4.25M +34,320 +1,761%
O
27
OrbiMed
New York
$6.99M -$14.9M -120,441 -77%
UBS AM
28
UBS AM
Illinois
$6.86M -$13.7K -111 -0.3%
Charles Schwab
29
Charles Schwab
California
$5.83M +$196K +1,581 +6%
FAM
30
Fred Alger Management
New York
$5.66M +$2.2M +17,753 +166%
WP
31
Woodline Partners
California
$5M +$2.34M +18,900 +302%
Goldman Sachs
32
Goldman Sachs
New York
$4.88M +$283K +2,289 +10%
PAMP
33
Polar Asset Management Partners
Ontario, Canada
$4.82M -$4.26M -34,400 -59%
WMSA
34
Weiss Multi-Strategy Advisers
New York
$4.22M +$2.63M +21,250 New
TD Asset Management
35
TD Asset Management
Ontario, Canada
$2.92M -$557K -4,500 -23%
SSA
36
Schonfeld Strategic Advisors
New York
$2.75M -$378K -3,051 -18%
N
37
Nuveen
North Carolina
$2.57M +$96.3K +778 +6%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$2.53M +$112K +905 +8%
Norges Bank
39
Norges Bank
Norway
$2.49M +$1.55M +12,538 New
Citadel Advisors
40
Citadel Advisors
Florida
$2.46M -$97.2K -785 -6%
Bank of America
41
Bank of America
North Carolina
$2.32M +$10.8K +87 +0.8%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$2.28M -$102K -826 -7%
Point72 Asset Management
43
Point72 Asset Management
Connecticut
$2.25M -$2.12M -17,150 -60%
UBS Group
44
UBS Group
Switzerland
$2.24M +$862K +6,963 +162%
Barclays
45
Barclays
United Kingdom
$1.95M +$384K +3,103 +46%
Jane Street
46
Jane Street
New York
$1.9M +$523K +4,226 +79%
TOCUITCONY
47
Trustees of Columbia University in the City of New York
New York
$1.82M – – –
Invesco
48
Invesco
Georgia
$1.62M +$617K +4,988 +158%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$1.59M +$75.8K +612 +8%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$1.59M -$570K -4,601 -37%
1
2
3 4 5

RAPT Hedge Fund Activity: Q4 2023 in Review

108 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2023, worth a combined $895M — up 55% from $578M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new RAPT positions and 8 closed out — a net gain of 13 holders — while 38 added to existing stakes and 36 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $20.6M. The largest seller was OrbiMed, cutting an estimated $14.9M.

  • 108 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2023, up from 96 in Q3 2023.
  • Funds reported $895M of RAPT Therapeutics stock for Q4 2023, up 55% quarter-over-quarter.
  • 21 funds opened new RAPT Therapeutics positions in Q4 2023 and 8 closed out, a net change of +13 holders.
  • The largest RAPT Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $20.6M added.
  • The largest RAPT Therapeutics seller in Q4 2023 was OrbiMed, an estimated $14.9M sold.

Based on aggregated 13F filings for Q4 2023.